中文摘要：

目的评价含胸腺肽免疫增强的自体CIK细胞联合IL-2（TCIL-2）方案治疗高龄弥漫大B细胞淋巴瘤的有效性和安全性。方法采集预先接受胸腺五肽免疫增强治疗的4例高龄弥漫大B细胞淋巴瘤（DLBCL）患者外周血单个核细胞，在体外经干扰素-γ（IFN-γ）、白介素-2（IL-2）、抗CD3单克隆抗体诱导成CIK细胞，回输细胞数为2×10^9 -3×10。个，回输后应用IL-2 100mU／d，皮下注射，连续10d。28d为1个周期，共完成24个周期的自体CIK细胞输注。观察治疗前后细胞免疫功能、肿瘤相关生物学指标变化。结果2例接受8个周期的CIK细胞输注，2例接受4个周期的输注，回输后所有患者未出现不良反应。CIK细胞治疗后CD3^＋、CD3^＋ CD8^＋、CD3^＋ CD56^＋细胞比例明显升高（P＜0．05），β2微球蛋白水平显著下降（P＜0．05）。3例达完全缓解，1例完成8周期的CIK细胞输注后一度达良好的部分缓解，但最终因急性心肌梗死和淋巴瘤持续进展而死亡。结论自体CIK细胞联合IL-2治疗高龄弥漫大B细胞淋巴瘤安全有效。

英文摘要：

Objective To assess the efficiency and safety of combined thymic peptide-enhanced autologous cytokine induced killer （CIK） cells and IL-2 in treatment of diffuse large B cell lymphoma in aged patients. Methods Peripheral blood mononuclear cells （PBMC） were collected from 4 aged patients with diffuse large B cell lymphoma. CIK cells were induced with in vitro interferon gamma （IFN- γ ）, IL-2 and anti-CD3 monoclonal antibody （mAb）. Immune function of the cells and tumor-related biological indexes of the patients were observed after 2 × 10^9 -3 × 109 autologous CIK cells were re-transfused into the patients each time and IL-2 100mU/d was subcutaneously injected for 10 days, 28 days a cycle for 24 cycles. Results Two patients received 8 cycles of CIK cells transfusion and 2 patients received 4 cycles of CIK cells transfusion. No adverse reaction occurred in them. The number of CD3^＋, CD3^＋ CD8^＋ and CD3^＋ CD56^＋was significantly greater and the serum β2-microglobulin level was markedly lower after CIK cells transfusion than before CIK cells transfusion（P〈0.05）. Complete remission was achieved in 3 patients and 1 patient died of acute large-area myocardial infarction and persistent progression of lymphoma although partial remission was achieved after 8 cycles of CIK cells transfusion. Conclusion Combined autologous CIK cells transfusion and IL-2 is safe and effective for large B cell lymphoma in aged patients.